Mastering LOE: Expert Strategies to Predict Drug Patent Expiry and Seize Generic Market Share
Executive Summary The global pharmaceutical industry is currently navigating a period of unprecedented structural transformation. We are standing on the
December 2025
The Gray Zone: How 503B Pharmacies Navigate the Intersection of FDA Regulation and Drug Patents
In pharmaceuticals 503B outsourcing facilities occupy a unique and often contentious space. Born from the ashes of a public health
More Biopharmaceutical Competition, Better Products: Evidence From Tariff Cuts
On one hand, the pharmaceutical sector is driven by a scientific and economic imperative that thrives on openness: the seamless
More Biopharmaceutical Competition, Better Products: Evidence From Tariff Cuts Read Post »
The Real Cost of Challenging Big Pharma Patents
Pharma IP teams, hedge funds, and biosimilar developers treat a Paragraph IV filing as a legal event. It is not.
The Real Cost of Challenging Big Pharma Patents Read Post »
The Repurposing Revolution: Unlocking Hidden Value in Pharmaceutical Patents
Introduction: Beyond Serendipity – The New Strategic Imperative For decades, the pharmaceutical industry has operated on a model of heroic,
The Repurposing Revolution: Unlocking Hidden Value in Pharmaceutical Patents Read Post »
